Modelling time‐course relationships with multiple treatments: Model‐based network meta‐analysis for continuous summary outcomes

Abstract

Time-course MBNMA provides a statistically robust framework for synthesising evidence on multiple treatments at multiple time points. The use of placebo-controlled studies in drug-development means there is limited potential for inconsistency. The methods can inform drug-development decisions and provide the rigour needed in the reimbursement decision-making process.